Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights progress in perioperative neuroprotection, mechanistic drivers of postoperative cognitive disorders, and practical anesthesia strategies that improve recovery and reduce opioid use. A phase 2 randomized trial established feasibility and safety of the apoE‑mimetic CN‑105 for older surgical patients, a preclinical study identified microglial RUVBL2-driven metabolic reprogramming as a targetable mechanism for postoperative delirium, and randomized tr
Summary
This week’s anesthesiology literature highlights progress in perioperative neuroprotection, mechanistic drivers of postoperative cognitive disorders, and practical anesthesia strategies that improve recovery and reduce opioid use. A phase 2 randomized trial established feasibility and safety of the apoE‑mimetic CN‑105 for older surgical patients, a preclinical study identified microglial RUVBL2-driven metabolic reprogramming as a targetable mechanism for postoperative delirium, and randomized trials showed GA‑sparing/regional approaches can meaningfully improve early recovery metrics.
Selected Articles
1. Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients: The Phase 2 MARBLE Randomized Clinical Trial.
Triple‑blind phase 2 randomized trial (n=186) showed perioperative IV CN‑105 is feasible, achieved high on‑time dosing, and did not increase adverse events; per‑patient grade ≥2 adverse events were fewer with CN‑105. Trends toward lower delirium incidence and severity were observed but were not statistically significant, and CSF cytokine changes at 24 hours did not differ.
Impact: First rigorous surgical phase 2 RCT testing an apoE‑mimetic for perioperative neuroinflammation/delirium, establishing safety and operational feasibility and enabling a planned phase 3 efficacy trial.
Clinical Implications: Current evidence supports safety and trial feasibility rather than routine use. Centers should consider enrolling eligible patients into phase 3 trials and prepare CSF/blood biomarker workflows to enable mechanistic and subgroup analyses (e.g., APOE ε4 carriers).
Key Findings
- High on‑time dosing achieved (94.6% of CN‑105 doses administered within window) and no increase in grade ≥2 adverse event rates versus placebo.
- Median grade ≥2 adverse events per patient were lower with CN‑105 (median 1 vs 2; P=0.03).
- Delirium incidence was numerically lower (19.3% vs 26.5%) and severity trended lower with CN‑105 but without statistical significance; CSF cytokine changes at 24 h showed no significant differences.
2. RUVBL2 Regulates Microglia Metabolic Reprogramming to Mediate Stress Granules Aggregation Exacerbating Postoperative Delirium in Aged Mild Cognitive Impairment Rats.
Preclinical mechanistic study showed that in aged MCI rats, hippocampal microglia shift from OXPHOS to glycolysis with upregulated RUVBL2; lentiviral RUVBL2 knockdown restored OXPHOS (OCR↑, ECAR↓), reduced stress granule aggregation and neuroinflammation, and improved hippocampal‑dependent cognition—identifying RUVBL2 as a potential therapeutic target for postoperative delirium.
Impact: Uncovers a novel microglial metabolic checkpoint (RUVBL2) linking metabolic reprogramming and stress granule biology to postoperative delirium pathogenesis—providing a mechanistic rationale for metabolic or gene‑targeted perioperative interventions.
Clinical Implications: Translational work should validate RUVBL2 signatures in human perioperative biospecimens and evaluate pharmacologic metabolic modulators or RUVBL2 inhibitors as adjuncts to established delirium prevention bundles.
Key Findings
- Aged MCI rat microglia reprogrammed from OXPHOS to glycolysis postoperatively with increased RUVBL2 expression correlating with POD progression.
- Lentiviral RUVBL2 knockdown decreased ECAR, increased OCR, reduced stress granule aggregation and neuroinflammation, and improved hippocampal cognitive measures.
- Direct metabolic flux measurements (ECAR/OCR) and in vivo MRI supported the mechanistic link between RUVBL2, metabolism, and cognitive outcomes.
3. Recovery quality with regional anesthesia and dexmedetomidine sedation versus general anesthesia for ambulatory breast cancer surgery: A randomized trial.
Randomized trial (n=96) found regional anesthesia (PECS and intercostal blocks) with dexmedetomidine sedation produced higher QoR‑15 at 6 hours (median 142 vs 132), less early postoperative pain and rescue analgesia, markedly lower PONV (2% vs 27%), and fewer intraoperative hemodynamic fluctuations versus general anesthesia for ambulatory breast‑conserving surgery.
Impact: Offers randomized, clinically actionable evidence that a GA‑sparing regional approach with dexmedetomidine improves early recovery and side‑effect profile in ambulatory breast surgery—informing anesthetic choices for high‑volume procedures.
Clinical Implications: For suitable ambulatory breast procedures, consider PECS/intercostal blocks with dexmedetomidine sedation to enhance early recovery, reduce PONV and opioid rescue needs, while ensuring team expertise and monitoring for dexmedetomidine‑related bradycardia/hypotension.
Key Findings
- QoR‑15 at 6 h higher with regional+dexmedetomidine (median 142 vs 132; p<0.01).
- Lower early postoperative pain and rescue analgesia use (27% vs 56% rescue analgesia; p<0.01) and markedly reduced PONV (2% vs 27%; p<0.01).
- Fewer intraoperative hypotension episodes and smaller hemodynamic fluctuations with regional anesthesia.